Skip Ribbon Commands
Skip to main content
Back to Search Results

A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC),

​HER2-, Hormone Receptor +, Advanced Breast Ca

Condition: Intervention: Phase:
Breast Cancer II
Status: Open (Show results)
Volunteers Required: Yes
Published Date: 20 October 2020

Term of Use/Disclaimer

All information provided within this web and mobile application is intended for general information and is provided on the understanding that no surgical and medical advice or recommendation is being rendered. Please do not disregard the professional advice of your physician.

Principal Investigator

Senior Consultant

Organised by

National Cancer Centre Singapore
Last updated on